Results 61 to 70 of about 887,943 (333)

Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics

Nature Communications, 2020
Clonal diversity is a consequence of cancer cell evolution driven by Darwinian selection. Precise characterization of clonal architecture is essential to understand the evolutionary history of tumor development and its association with treatment ...
Kiyomi Morita, Kiyomi Morita, Feng Wang, Katharina Jahn, Katharina Jahn, T. Hu, Tomoyuki Tanaka, Yuya Sasaki, Jack Kuipers, Jack Kuipers, S. Loghavi, Sa A. Wang, Yuanqing Yan, Ken Furudate, Ken Furudate, J. Matthews, L. Little, C. Gumbs, Jianhua Zhang, Xingzhi Song, Erika J. Thompson, K. Patel, C. Bueso-Ramos, C. Dinardo, F. Ravandi, E. Jabbour, M. Andreeff, J. Cortes, K. Bhalla, G. Garcia-Manero, H. Kantarjian, M. Konopleva, Daisuke Nakada, N. Navin, N. Beerenwinkel, N. Beerenwinkel, P. Futreal, Koichi Takahashi   +37 more
semanticscholar   +1 more source

One Stone, Two Birds: N6-Methyladenosine RNA Modification in Leukemia Stem Cells and the Tumor Immune Microenvironment in Acute Myeloid Leukemia

Frontiers in Immunology, 2022
Acute myeloid leukemia is the most common acute leukemia in adults, with accumulation of abundant blasts and impairment of hematogenic function. Despite great advances in diagnosis and therapy, the overall survival of patients with acute myeloid leukemia
Xianfeng Ouyang, Xianfeng Ouyang, Yuping Gong   +2 more
doaj   +1 more source

Safe discontinuation of nilotinib in a patient with chronic myeloid leukemia: a case report [PDF]

, 2014
Case presentation. We report the case of a 64-year-old Caucasian man diagnosed with chronic-phase chronic myeloid leukemia in April 2005. After 4 years of treatment with imatinib, he became intolerant to the drug and was switched to nilotinib.
CAOCCI, GIOVANNI, Greco M, LA NASA, GIORGIO   +2 more
core   +2 more sources

Flotetuzumab as Salvage Immunotherapy for Refractory Acute Myeloid Leukemia.

Blood, 2020
Despite recent advancements, approximately 50% of patients with acute myeloid leukemia (AML) do not respond to induction therapy (primary induction failure, PIF) or relapse after
G. Uy, Ibrahim Aldoss, M. Foster, P. Sayre, M. Wieduwilt, A. Advani, J. Godwin, M. Arellano, K. Sweet, A. Emadi, F. Ravandi, H. Erba, M. Byrne, L. Michaelis, M. Topp, N. Vey, F. Ciceri, M. Carrabba, S. Paolini, G. Huls, M. Jongen‐Lavrencic, M. Wermke, P. Chevallier, E. Gyan, C. Récher, P. Stiff, K. Pettit, B. Löwenberg, S. Church, Erica Anderson, J. Vadakekolathu, Marianne T Santaguida, M. Rettig, J. Muth, Teia Curtis, Erin Fehr, Kuo Guo, Jian Zhao, Ouiam Bakkacha, K. Jacobs, K. Tran, P. Kaminker, M. Kostova, E. Bonvini, R. Walter, J. Davidson-Moncada, S. Rutella, J. Dipersio   +47 more
semanticscholar   +1 more source

FHL2 regulates hematopoietic stem cell functions under stress conditions. [PDF]

, 2015
FHL2, a member of the four and one half LIM domain protein family, is a critical transcriptional modulator. Here, we identify FHL2 as a critical regulator of hematopoietic stem cells (HSCs) that is essential for maintaining HSC self-renewal under ...
Chen, J, Fan, R, Hou, Y, Hou, Y, Jiang, Y, Li, L, Li, W, Mittal, N, Peace, D, Qian, Z, Wang, X, Wu, W, Zhu, T   +12 more
core   +2 more sources

SnapShot: Acute Myeloid Leukemia [PDF]

Cancer Cell, 2012
20%-25% (28%-35%); High blast count; Poor prognosisespecially in cases with high mutant to WT allelic ratio5%-7% (10%-14%); Prognostic impact remains controversial10% (9%-14%); Enriched in CBF AML; Prognosis ...
Ghulam J. Mufti, Chi Wai Eric So, Bernd B. Zeisig, Austin G. Kulasekararaj   +3 more
openaire   +2 more sources

Insights into PI3K/AKT signaling in B cell development and chronic lymphocytic leukemia

FEBS Letters, EarlyView.
This Review explores how the phosphoinositide 3‐kinase and protein kinase B pathway shapes B cell development and drives chronic lymphocytic leukemia, a common blood cancer. It examines how signaling levels affect disease progression, addresses treatment challenges, and introduces novel experimental strategies to improve therapies and patient outcomes.
Maike Buchner
wiley   +1 more source

Anterior myeloid sarcoma revealing acute myeloid leukemia: Case report

Egyptian Journal of Chest Disease and Tuberculosis, 2016
Myeloid sarcoma (MS) is a tumor mass of myeloblasts or immature myeloid cells occurring in an extramedullary site or in the bone and generally precedes or reveals myeloid leukemia. It rarely occurs in the mediastinum.
H. Slimani, L. Achaachi, Y. Benbaba, L. Herrak, K. Znati, M. Ftouh   +5 more
doaj   +1 more source

Mutations in pathways depending on BRCA1 and BRCA2 may increase cancer risks from an environmental carcinogen [PDF]

, 2011
Recently, the President’s Cancer Panel [2008-2009] protested that preventive action is not taken when uncertainty exists about potential harm from a chemical, because the US regulatory approach demands that a hazard be incontrovertibly ...
Bernard Friedenson
core   +2 more sources

Bosutinib for Chronic Myeloid Leukemia [PDF]

Rare Cancers and Therapy, 2015
In recent years the availability of several tyrosine kinase inhibitors (TKI) in the therapeutic armamentarium for chronic myeloid leukemia has dramatically changed the objectives and expectations of healthcare providers and patients. For many, but not all, patients the forerunner of TKI, imatinib, is still an excellent treatment option.
Massimo Breccia, Gianni Binotto
openaire   +3 more sources